100 related articles for article (PubMed ID: 20112426)
1. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.
Hennig M; Yip-Schneider MT; Wentz S; Wu H; Hekmatyar SK; Klein P; Bansal N; Schmidt CM
Hepatology; 2010 Apr; 51(4):1218-25. PubMed ID: 20112426
[TBL] [Abstract][Full Text] [Related]
2. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.
Wentz SC; Wu H; Yip-Schneider MT; Hennig M; Klein PJ; Sebolt-Leopold J; Schmidt CM
J Gastrointest Surg; 2008 Jan; 12(1):30-7. PubMed ID: 17987349
[TBL] [Abstract][Full Text] [Related]
3. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
[TBL] [Abstract][Full Text] [Related]
4. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
Liu D; Xing M
Thyroid; 2008 Aug; 18(8):853-64. PubMed ID: 18651802
[TBL] [Abstract][Full Text] [Related]
6. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
7. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
Huang W; Yang AH; Matsumoto D; Collette W; Marroquin L; Ko M; Aguirre S; Younis HS
J Ocul Pharmacol Ther; 2009 Dec; 25(6):519-30. PubMed ID: 19929595
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.
Brown AP; Carlson TC; Loi CM; Graziano MJ
Cancer Chemother Pharmacol; 2007 Apr; 59(5):671-9. PubMed ID: 16944149
[TBL] [Abstract][Full Text] [Related]
9. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.
Legrier ME; Yang CP; Yan HG; Lopez-Barcons L; Keller SM; Pérez-Soler R; Horwitz SB; McDaid HM
Cancer Res; 2007 Dec; 67(23):11300-8. PubMed ID: 18056456
[TBL] [Abstract][Full Text] [Related]
10. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
11. Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.
Paulo JA; McAllister FE; Everley RA; Beausoleil SA; Banks AS; Gygi SP
Proteomics; 2015 Jan; 15(2-3):462-73. PubMed ID: 25195567
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
13. Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo.
Houweling M; Abdul UK; Brahm C; Lagerweij T; Heukelom S; Koken PW; Honeywell R; Wedekind LE; Peters GJ; Verheul H; Sminia P; Noske D; Wurdinger T; Westerman BA
J Cancer Res Clin Oncol; 2023 Jan; 149(1):297-305. PubMed ID: 36451044
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Andersen NJ; Nickoloff BJ; Dykema KJ; Boguslawski EA; Krivochenitser RI; Froman RE; Dawes MJ; Baker LH; Thomas DG; Kamstock DA; Kitchell BE; Furge KA; Duesbery NS
Mol Cancer Ther; 2013 Sep; 12(9):1701-14. PubMed ID: 23804705
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Wu CH; Wu X; Zhang HW
J Surg Res; 2016 Dec; 206(2):371-379. PubMed ID: 27884331
[TBL] [Abstract][Full Text] [Related]
16. Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib).
El-Hoss J; Kolind M; Jackson MT; Deo N; Mikulec K; McDonald MM; Little CB; Little DG; Schindeler A
Bone; 2014 Feb; 59():151-61. PubMed ID: 24269278
[TBL] [Abstract][Full Text] [Related]
17. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
[TBL] [Abstract][Full Text] [Related]
18. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
Ishida N; Fukazawa T; Maeda Y; Yamatsuji T; Kato K; Matsumoto K; Shimo T; Takigawa N; Whitsett JA; Naomoto Y
Exp Cell Res; 2015 Jul; 335(2):197-206. PubMed ID: 25839409
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts.
Andersen NJ; Boguslawski EB; Kuk CY; Chambers CM; Duesbery NS
Int J Oncol; 2015 Jul; 47(1):71-80. PubMed ID: 25955301
[TBL] [Abstract][Full Text] [Related]
20. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
